Jacobson, C. A., Chavez, J. C., Sehgal, A. R., William, B. M., Munoz, J., Salles, G., . . . Neelapu, S. S. (2022). Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial. The lancet oncology, 23(1), 91-103. https://doi.org/10.1016/S1470-2045(21)00591-X
Citácia podle Chicago (17th ed.)Jacobson, Caron A., et al. "Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5): A Single-arm, Multicentre, Phase 2 Trial." The Lancet Oncology 23, no. 1 (2022): 91-103. https://doi.org/10.1016/S1470-2045(21)00591-X.
Citácia podľa MLA (8th ed.)Jacobson, Caron A., et al. "Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5): A Single-arm, Multicentre, Phase 2 Trial." The Lancet Oncology, vol. 23, no. 1, 2022, pp. 91-103, https://doi.org/10.1016/S1470-2045(21)00591-X.